These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 18662145

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T.
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract] [Full Text] [Related]

  • 5. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E, Park J, Vidhun J, Campese V.
    Arch Intern Med; 2009 Jun 08; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract] [Full Text] [Related]

  • 6. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention.
    Gradman AH.
    Am Heart J; 2009 Jun 08; 157(6 Suppl):S1-6. PubMed ID: 19450719
    [No Abstract] [Full Text] [Related]

  • 7. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T.
    N Engl J Med; 2008 Sep 04; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacological differences between inhibitor drugs of the renin-angiotensin aldosterone system].
    Méndez-Durán A.
    Rev Med Inst Mex Seguro Soc; 2011 Sep 04; 49(1):45-52. PubMed ID: 21513660
    [Abstract] [Full Text] [Related]

  • 9. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D, Krzesinski JM, Scheen AJ.
    Rev Med Suisse; 2008 Aug 27; 4(168):1792-7. PubMed ID: 18814762
    [Abstract] [Full Text] [Related]

  • 10. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
    Robles NR, Ruiz Jiménez B, Hernández Gallego R, Ruiz-Calero R, Sánchez Casado E, Cubero JJ.
    Eur J Intern Med; 2009 Mar 27; 20(2):186-9. PubMed ID: 19327610
    [Abstract] [Full Text] [Related]

  • 11. The benefits of renin-angiotensin blockade in hypertension are dependent on blood-pressure lowering.
    Bidani AK, Griffin KA.
    Nat Clin Pract Nephrol; 2006 Oct 27; 2(10):542-3. PubMed ID: 17003827
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acute renal failure associated to renin angiotensin system (RAS) inhibitors--its burden in a nephrology department.
    Navarro I, Poveda R, Torras J, Castelao AM, Grinyó JM.
    Nephrol Dial Transplant; 2008 Jan 27; 23(1):413-4. PubMed ID: 17890250
    [No Abstract] [Full Text] [Related]

  • 17. Combinations of renin-angiotensin-aldosterone system antagonists: true advantages?
    Veglio F, Puglisi E, Milan A, Mulatero P.
    Curr Pharm Des; 2012 Jan 27; 18(7):952-7. PubMed ID: 22283773
    [Abstract] [Full Text] [Related]

  • 18. The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B.
    Kidney Blood Press Res; 2008 Jan 27; 31(6):404-10. PubMed ID: 19092257
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.